Previous Close | 2.5200 |
Open | 2.5600 |
Bid | 2.4700 x 1800 |
Ask | 2.5500 x 1400 |
Day's Range | 2.4900 - 2.5700 |
52 Week Range | 1.5000 - 3.1550 |
Volume | 65,089 |
Avg. Volume | 75,696 |
Market Cap | 76.875M |
Beta (3Y Monthly) | 2.59 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.5180 |
Earnings Date | Nov 5, 2019 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.00 |
Top Ranked Momentum Stocks to Buy for December 3rd
SAN DIEGO, Nov. 26, 2019 -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
Q3 2019 Otonomy Inc Earnings Call
Otonomy (OTIC) delivered earnings and revenue surprises of 26.67% and -59.68%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s diseaseBroadest pipeline in neurotology field expanded to include gene.
SAN DIEGO, Oct. 29, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
Every investor in Otonomy, Inc. (NASDAQ:OTIC) should be aware of the most powerful shareholder groups. Institutions...
Otonomy (OTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GAINESVILLE, Fla. and CAMBRIDGE, Mass. and SAN DIEGO, Oct. 01, 2019 -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human.
SAN DIEGO, Sept. 26, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 1/2 clinical trial of OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF), in patients with hearing loss. “Recent scientific research in the neurotology field has demonstrated that damage or loss of synaptic connections between inner ear hair cells and spiral ganglion neurons, known as cochlear synaptopathy, is involved in the hearing difficulty that many people experience in a loud environment, and that this pathology may also play a role in age-related and noise-induced hearing loss,” said Andrea Vambutas, M.D., Director for the Center of Hearing & Balance at the New York Head & Neck Institute.
Q2 2019 Otonomy Inc Earnings Call
Clinical-stage programs on track with results expected from three trials in 2020Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. EDT.
SAN DIEGO, July 25, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I...
SAN DIEGO, June 12, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
Q1 2019 Otonomy Inc Earnings Call
Otonomy (OTIC) delivered earnings and revenue surprises of 15.22% and -40.92%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The San Diego-based company said it had a loss of 39 cents per share. The biotechnology company posted revenue of $192,000 in the period. In the final minutes of trading on Monday, the company's shares ...
OTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020OTIPRIO® co-promotion agreement completed with Glenmark TherapeuticsOTIVIDEX™ Phase 3 trial.
NEW YORK, NY / ACCESSWIRE / May 6, 2019 / Otonomy, Inc. (NASDAQ: OTIC ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 6, 2019 at 4:30 PM Eastern Time. ...
MAHWAH, N.J., May 2, 2019 /PRNewswire/ -- Glenmark Therapeutics Inc., USA, a wholly-owned subsidiary of Glenmark Holding SA., today announced a co-promotion agreement with Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. Glenmark Therapeutics is dedicated to developing and commercializing a franchise of branded products for Glenmark Pharmaceuticals and is focused in the areas of respiratory and dermatology. Ryaltris™ (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg]), formerly GSP 301 Nasal Spray, is the company's leading respiratory pipeline asset and currently under review with the U.S. Food and Drug Administration (FDA) as a treatment for seasonal allergic rhinitis in patients 12 years and older.
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the signing of a co-promotion agreement with Glenmark Therapeutics Inc., USA, a wholly-owned subsidiary of Glenmark Holding SA., which is dedicated to building and commercializing a franchise of branded products for Glenmark Pharmaceuticals focused in the areas of respiratory and dermatology. This agreement provides Glenmark Therapeutics with an exclusive right to promote OTIPRIO (ciprofloxacin otic suspension) to ear, nose and throat (ENT) physician offices in the United States and its territories for the treatment of acute otitis externa (AOE) in patients 6 months of age and older due to Pseudomonas aeruginosa and Staphylococcus aureus.
SAN DIEGO, May 01, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2019 as well as provide a corporate update at 4:30 p.m. EDT on May 6, 2019. The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 8076448. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days.